Emerging drugs for acute lymphocytic leukemia

被引:4
|
作者
Mathisen, Michael S. [1 ]
Kantarjian, Hagop M. [2 ]
Jabbour, Elias J. [2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Pharm & Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
关键词
acute lymphoblastic leukemia; blinatumomab; inotuzumab; monoclonal antibodies; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TERM-FOLLOW-UP; TYROSINE KINASE INHIBITORS; MINIMAL RESIDUAL DISEASE; DOSE-INTENSIVE REGIMEN; HYPER-CVAD; INOTUZUMAB OZOGAMICIN; GEMTUZUMAB OZOGAMICIN; BRENTUXIMAB VEDOTIN;
D O I
10.1517/14728214.2014.872629
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Acute lymphoblastic leukemia (ALL) is typically treated with complex multi-agent chemotherapy regimens over a prolonged time period. Long-term outcomes depend on the age of the patient and the biological characteristics of the leukemic cells. While pediatric patients achieve cure more often than adults, therapy can continue to be improved for all patients with this disease. Areas covered: The current management strategy for ALL is reviewed. Recently, targeted therapies have been shown to improve survival in subsets of patients, most notably in those with Philadelphia chromosome-positive ALL or with leukemic cells that express the surface antigen CD20. Several innovative compounds are under investigation, and the most promising ones to date will be discussed. Expert opinion: The incorporation of monoclonal antibody therapy represents a targeted and powerful approach to the management of ALL. Bispecific T-cell engaging agents, such as blinatumomab, are able to facilitate immune-mediated killing of leukemia cells. Immunoconjugates (i.e., monoclonal antibodies linked to various cytotoxins) allow small doses of very potent chemotherapy to be delivered directly to a leukemia cell with hope of sparing normal tissue. As the genetic and molecular characterization of ALL is more completely understood, patients will receive treatment plans that are more individualized than previously possible.
引用
收藏
页码:37 / 50
页数:14
相关论文
共 50 条
  • [1] Emerging immunological drugs for chronic lymphocytic leukemia
    Robak, Pawel
    Smolewski, Piotr
    Robak, Tadeusz
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2015, 20 (03) : 423 - 447
  • [2] Novel and Emerging Drugs for Chronic Lymphocytic Leukemia
    Isfort, S.
    Cramer, P.
    Hallek, M.
    [J]. CURRENT CANCER DRUG TARGETS, 2012, 12 (05) : 471 - 483
  • [3] Novel and Emerging Drugs for Acute Lymphoblastic Leukemia
    Lech-Maranda, E.
    Mlynarski, W.
    [J]. CURRENT CANCER DRUG TARGETS, 2012, 12 (05) : 505 - 521
  • [4] Novel and Emerging Drugs for Acute Myeloid Leukemia
    Stein, E. M.
    Tallman, M. S.
    [J]. CURRENT CANCER DRUG TARGETS, 2012, 12 (05) : 522 - 530
  • [5] Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia
    Alvarado, Yesid
    Apostolidou, Effrosyni
    Swords, Ronan
    Giles, Francis J.
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2007, 12 (01) : 165 - 179
  • [6] Acute lymphocytic leukemia
    Lara, Diane
    Gauthier, Martin
    [J]. HEMATOLOGIE, 2014, 20 (02): : 116 - 129
  • [7] Epigenetics Directing Therapy in Acute Lymphocytic Leukemia: Emerging Roles and New Therapies
    Bernt, Kathrin M.
    [J]. BLOOD, 2015, 126 (23)
  • [8] ACUTE UNDIFFERENTIATED LEUKEMIA - ACUTE LYMPHOCYTIC LEUKEMIA OF ADULT
    ABBREDERIS, K
    SCHMALZL, F
    [J]. MEDIZINISCHE KLINIK, 1974, 69 (34) : 1364 - 1368
  • [9] Novel and Emerging Drugs for Acute Myeloid Leukemia: Pharmacology and Therapeutic Activity
    Robak, T.
    Szmigielska-Kaplon, A.
    Pluta, A.
    Grzybowska-Izydorczyk, O.
    Wolska, A.
    Czemerska, M.
    Wierzbowska, A.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2011, 18 (05) : 638 - 666
  • [10] ACUTE LYMPHOCYTIC LEUKEMIA IN CHILDREN
    SIMONE, JV
    AUR, RJA
    HUSTU, HO
    VERZOSA, M
    [J]. CANCER, 1975, 36 (02) : 770 - 774